Monty Pal, MD

GU Oncology Now

<p>Dr. Monty Pal discusses impactful data released at the recent ASCO GU meeting, including thoughts on the CheckMate 9ER study and its findings on treatment outcomes based on site of metastasis, as well as quality of life implications for patients treated with nivolumab/cabozantinib.</p>


Monty Pal, MD, Discusses Key RCC Highlights From ASCO GU

ASCO GU Symposium 2024

CheckMate 9ER, 67T and KEYNOTE-564 are discussed.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe